The impact of known breast cancer polygenes on critical illness insurance

Research output: Contribution to journalArticle

Abstract

Genetic studies indicate that the inherited risk of breast cancer is mediated by the well-studied major genes BRCA1 and BRCA2, and a polygenic component, probably with many genes each making a small contribution. Recently, seven polygenes have been found (Pharoah et al., 2008) contributing an estimated 3.6% of all familial risk (Easton et al., 2007) This suggests that the polygenic component may involve well over 100 genetic loci.

We extrapolate these new results into a polygenic model with 147 genetic loci and simulate lifetimes of families to calculate the premium ratings appropriate for a family history of breast or ovarian cancer. We model the adverse selection costs arising from restricting the use of genetic test information in critical illness insurance underwriting in light of new European legislation banning the use of gender for insurance underwriting. In this setting we conrm the overall conclusion of Macdonald & McIvor (2009) that the polygene confers higher adverse selection risk than the BRCA genes. We establish that their three-gene polygenic model does not overly inflate the insurance costs attributable to a polygenic component of breast cancer risk under a model with 147 polygenes.
Original languageEnglish
Pages (from-to)141-171
Number of pages31
JournalScandinavian Actuarial Journal
Volume2015
Issue number2
Early online date10 Jun 2013
DOIs
Publication statusPublished - 2015

Fingerprint

Gene
Illness
Breast cancer
Insurance
Underwriting
Adverse selection costs
Cancer
Adverse selection
Rating
Costs
European legislation
Premium

Cite this

@article{a08e6bf749d94387ab0f5fbfe93ec614,
title = "The impact of known breast cancer polygenes on critical illness insurance",
abstract = "Genetic studies indicate that the inherited risk of breast cancer is mediated by the well-studied major genes BRCA1 and BRCA2, and a polygenic component, probably with many genes each making a small contribution. Recently, seven polygenes have been found (Pharoah et al., 2008) contributing an estimated 3.6{\%} of all familial risk (Easton et al., 2007) This suggests that the polygenic component may involve well over 100 genetic loci.We extrapolate these new results into a polygenic model with 147 genetic loci and simulate lifetimes of families to calculate the premium ratings appropriate for a family history of breast or ovarian cancer. We model the adverse selection costs arising from restricting the use of genetic test information in critical illness insurance underwriting in light of new European legislation banning the use of gender for insurance underwriting. In this setting we conrm the overall conclusion of Macdonald & McIvor (2009) that the polygene confers higher adverse selection risk than the BRCA genes. We establish that their three-gene polygenic model does not overly inflate the insurance costs attributable to a polygenic component of breast cancer risk under a model with 147 polygenes.",
author = "Craig Adams and Catherine Donnelly and Macdonald, {Angus Smith}",
year = "2015",
doi = "10.1080/03461238.2013.794520",
language = "English",
volume = "2015",
pages = "141--171",
journal = "Scandinavian Actuarial Journal",
issn = "0346-1238",
publisher = "Taylor & Francis",
number = "2",

}

The impact of known breast cancer polygenes on critical illness insurance. / Adams, Craig; Donnelly, Catherine; Macdonald, Angus Smith.

In: Scandinavian Actuarial Journal, Vol. 2015, No. 2, 2015, p. 141-171.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The impact of known breast cancer polygenes on critical illness insurance

AU - Adams, Craig

AU - Donnelly, Catherine

AU - Macdonald, Angus Smith

PY - 2015

Y1 - 2015

N2 - Genetic studies indicate that the inherited risk of breast cancer is mediated by the well-studied major genes BRCA1 and BRCA2, and a polygenic component, probably with many genes each making a small contribution. Recently, seven polygenes have been found (Pharoah et al., 2008) contributing an estimated 3.6% of all familial risk (Easton et al., 2007) This suggests that the polygenic component may involve well over 100 genetic loci.We extrapolate these new results into a polygenic model with 147 genetic loci and simulate lifetimes of families to calculate the premium ratings appropriate for a family history of breast or ovarian cancer. We model the adverse selection costs arising from restricting the use of genetic test information in critical illness insurance underwriting in light of new European legislation banning the use of gender for insurance underwriting. In this setting we conrm the overall conclusion of Macdonald & McIvor (2009) that the polygene confers higher adverse selection risk than the BRCA genes. We establish that their three-gene polygenic model does not overly inflate the insurance costs attributable to a polygenic component of breast cancer risk under a model with 147 polygenes.

AB - Genetic studies indicate that the inherited risk of breast cancer is mediated by the well-studied major genes BRCA1 and BRCA2, and a polygenic component, probably with many genes each making a small contribution. Recently, seven polygenes have been found (Pharoah et al., 2008) contributing an estimated 3.6% of all familial risk (Easton et al., 2007) This suggests that the polygenic component may involve well over 100 genetic loci.We extrapolate these new results into a polygenic model with 147 genetic loci and simulate lifetimes of families to calculate the premium ratings appropriate for a family history of breast or ovarian cancer. We model the adverse selection costs arising from restricting the use of genetic test information in critical illness insurance underwriting in light of new European legislation banning the use of gender for insurance underwriting. In this setting we conrm the overall conclusion of Macdonald & McIvor (2009) that the polygene confers higher adverse selection risk than the BRCA genes. We establish that their three-gene polygenic model does not overly inflate the insurance costs attributable to a polygenic component of breast cancer risk under a model with 147 polygenes.

U2 - 10.1080/03461238.2013.794520

DO - 10.1080/03461238.2013.794520

M3 - Article

VL - 2015

SP - 141

EP - 171

JO - Scandinavian Actuarial Journal

JF - Scandinavian Actuarial Journal

SN - 0346-1238

IS - 2

ER -